Summary Presentation of endogenous antigenic peptides to cytotoxic T lymphocytes is mediated by the major histocompatibility complex (MHC) class I molecules. For the stable assembly of MHC class I complex it is necessary that the antigenic peptide is transported by the MHC-encoded transporters TAP-1 and TAP-2 into a pre-Golgi region. T-cell-mediated host-vs-tumour response might therefore depend on the presence of these molecules on tumour cells. The presence of MHC class I antigens and TAP-1 was studied in a series of 93 resection specimens of non-small-cell lung carcinomas (NSCLCs) by immunohistochemical methods using antibodies against the assembled class I molecule, beta2-microglobulin (02-m), heavy-chain A locus, A2 allele and TAP-1 protein. Eighty-six patients were included in the survival analysis. Total loss of class I molecule was observed in 38% of the cases and was usually accompanied by loss of ,2-m and of heavy chain A locus. Selective loss of A locus was seen in 8.3% and of A2 allele in 27% of the cases. TAP-1 loss was always combined with P2-m and/or heavy chain A locus loss. No correlation was found between the expressional status of any of the above molecules, including the selective A2 allelic loss and histological type, degree of differentiation, tumoral stage, nodal stage and survival. Our findings suggest that loss of antigen-presenting molecules (including both MHC class I alleles and TAP-1) is a frequent event in lung cancer. However, the immunophenotypic profile of MHC class I and TAP-1 seems to be unrelated in vivo to the phenotype, growth or survival of NSCLC.
The major histocompatibility complex (MHC) comprises an array of genes located on chromosome 6 in humans and encodes several sets of immunoregulatory molecules-the classical transplantation antigens (class I), the immune response-associated antigens (class II) and complement genes (class III) (Dausset, 1981) . MHC class I molecules are polymorphic transmembrane glycoproteins composed of two polypeptide chains. The heavy chain (mol. wt. 4.5 kDa) is highly polymorphic and encoded by a group of closely linked loci, HLA-A, -B and -C. Its extracellular portion forms three domains al, a2, a3 (each approximately 90 amino acids long), which are coded by separate exons, while P2-m is nonpolymorphic and encoded by a different gene on chromosome 15. The interaction of P2-m with the o3 extracellular domain of the heavy chain plays a crucial role in the functional expression of the final product. Equally important in the formation of functional MHC class I molecules is the interaction of heavy-chain P2-m with the antigenic peptides (Arce-Gomez et al., 1978; Ploegh et al., 1981; Bodmer, 1987; Townsend et al., 1990) .
MHC class I molecules are widely distributed on most nucleated cells, with the exception of sperm, trophoblast, neurons and hepatocytes (Daar et al., 1984) . They regulate the ability of cytotoxic T lymphocytes (CTLs) to recognise antigens (Zinkernagel et al., 1979) whereas natural killer cell cytotoxicity has been shown to be inversely correlated with the degree of class I expression (Karre et al., 1986) . MHC class I molecules present predominantly endogenous antigens, which are derived from the cytoplasmic pool and assembled within the endoplasmic reticulum with newly synthesised class I and P2-m . These antigenic peptides are transported by a protein complex carrier into the pre-Golgi regions. These transporters of antigenic peptides are heterodimers composed of the products of two genes (TAP-I and TAP-2) located in the class II region of the MHC. Recently it was also shown that a chaperone molecule, calnexin, mediates heavy-chain-P2-m dimerisation and binding of the dimers to TAP molecules facilitates their assembly with TAP-transported peptides. (Trowsdale et al., 1990; Kleijmeer et al., 1992; Spies et al., 1992; Ortman et al., 1994) .
There is an ever increasing body of evidence that suggests that surface MHC class I antigen expression is altered on human tumours, in the sense of a loss or down-regulation of these molecules (Orgad et al., 1985; Festenstein and Garrido, 1986; Rees et al., 1988; Lopez-Nevot et al., 1989; Wintzer et al., 1990; Goepel et al., 1991) . Recently similar findings were also described regarding the immunophenotype of TAP-1 in cervical and colorectal tumours (Cromme et al., 1994; Kaklamanis et al., 1994) . There have been only a few studies on the expression of these antigens in lung cancer (Doyle, 1985; Funa et al., 1986; Diimmrich et al., 1990; Redondo et al., 1991a, b) and these deal mainly with alterations of P2-m and heavy chains.
The present study was undertaken to investigate the expression of MHC class I antigens along with that of TAP-1 protein in a large series of non-small-cell lung carcinomas (NSCLCs) and to examine its relationship with clinicopathological data. 
Materials and methods

Patients
Immunohistochemistry
Cryostat sections (7 mm thick) were fixed in acetone for 10 min at room temperature, left to dry overnight and stored at -20°C until required for staining. Immunohistochemical staining was performed using the alkaline phosphatase-antialkaline phosphatase (APAAP) method as described previously (Cordell et al., 1984) . For the polyclonal antibody AK1-7 a single modification of this technique was made, using an incubation step of mouse-anti-rabbit immunoglobulin.
Assessment of staining
Microscopic examination of immunohistochemically stained sections was carried out by two observers. The whole section was screened for the distribution of HLA antigens but areas of obvious tumour necrosis were avoided for counting. Normal respiratory epithelium and inflammatory lymphoid cells were used in each case as a control. Thus, a particular antigen was only considered to be lost by the tumour if it was still expressed by the adjacent normal respiratory epithelium and the lymphocytes. The evaluation was semiquantitative. A tumour was scored as negative (-) Actuarial survival curves were plotted using the Kaplan-Meier method (Kaplan and Meier, 1958) . The statistical significance was calculated using the log-rank test (Peto et al., 1977) and the hazard ratio with a 95% confidence interval was calculated as described by Machin and Gardner (1989) . The homogeneity of age in the various subgroups was assessed by calculating the F-value with one-way analysis of variances (Armitage and Berry, 1987) .
Results
Tables I and II summarise the results of the immunohistochemical expression of HLA class I and TAP-1 in the groups of SQC and AC.
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Survival analysis
The results of the survival analysis on the series of 86 nonsmall-cell lung carcinoma according to the staining with the antibodies W6/32, TAP-1 and MA 2.1 are summarised in Table II (Table II) . There was no association of staining with any of these antibodies with tumour differentiation, T stage or N stage (data not shown). Survival curves were plotted also for the other two antibodies, BBM1 and HCA2, but no difference could be found (data not shown). No difference could be detected even when the groups of squamous cell and adenocarcinoma were examined separately (Figure 3) .
Discussion
In the present study we detected two types of alterations in the surface expression of MHC class I antigens by the neoplastic cells: total loss of MHC class I molecule and selective losses of HLA-A locus and A2 allele. Total loss of MHC class I molecule as evidenced by negative reaction to W6/32 was detected in 38% of our cases, a figure higher than those quoted in previous studies (Redondo et al., 1991a, b) . Selective losses of A locus and A2 allele were identified in 8.3% and 27% respectively. Our findings show that loss of the assembled molecule is not only due to loss of P2-m but also to loss of TAPI molecules and/or heavy chains.
Previous studies of lung cancer have shown no difference between P2-m and heavy chain expression (Doyle, 1985; Redondo et al., 1991b) . However, in our series we have seen such a difference in a small proportion of cases (9.1%). Such uncoordinated expression of 12-m and heavy chains has also been observed in colon carcinomas (Momburg et al., 1989) . It is also worthy of note that the failure to detect A locus or A2 allele is not necessarily associated with loss of the assembled class I molecule. This is similar to the situation in colon carcinomas (Rees et al., 1988; Kaklamanis et al., 1992) . Interestingly, loss of the transporter protein was always combined with P2-m and/or A locus loss and was invariably associated with lack of expression of the assembled class I molecule. This implies that in the absence of the transporter protein the antigenic peptide is not able to join the MHC class I molecule rendering the assembly of the heavy chains and P2-m impossible.
The mechanisms by which total or partial losses of HLA antigens occur are not yet well known. Theoretically, they might reflect underlying chromosomal abnormalities (e.g. translocations or deletions) in the short arm of chromosome 6 for the heavy chains and TAP-I or chromosome 15 for P2-m. However, there is no current evidence to support this.
In fact, molecular studies in lung carcinomas have failed to demonstrate rearrangements of class I genes in cases with abnormal surface expression of these antigens (Doyle et al., 1985; Redondo et al., 1991a) . A more plausible mechanism is that of transcriptional down-regulation of MHC class I genes, which could be related to the action of cellular oncogene products, such as c-myc oncoprotein. This has been shown to operate in SLCL tumours and cell lines (Doyle, 1985) . However, in NSCLC expression of class I antigens appears to be independent of c-myc expression. Alternatively, it has been hypothesised that a post-transcriptional mechanism may be involved in the differential expression of HLA-A, B, C products in NSCLC, since there is not always a close relation between the surface expression of these antigens and their mRNAs (Redondo et al., 1991a) . Moreover, einterferon-mediated regulation of HLA-gene subsets has been documented (Haken et al., 1989; Schmidt et al., 1990) .
The lack of association between MHC class I loss and degree of differentiation, in our study, is at variance with data from the literature relating a loss of these antigens in lung cancer to the degree of differentiation as well as to the presence of aneuploidy in NSCLC and to an increased mitotic rate (Dammrich et al., 1990; Redondo et al., 1991b) . Based upon these findings it has been suggested that MHC class I loss is an indication of a more aggressive phenoptype and of a more rapid tumour growth. However, no relationship with the tumoral or nodal stage was found in the studies of Dammrich et al. (1990) and Redondo et al. (1991b) , in concordance with the results of the present study.
Experiments in murine models have shown that the loss of MHC class I antigen expression allows tumour growth and metastasis formation by escape from T-cell-mediated surveillance (Hui et al., 1984; Tanaka et al., 1985; Wallich et al., 1985) . Following this line of argument it was tempting to speculate that tumours lacking the above antigens would be prone to pursue a more unfavourable clinical course as compared with those with normal expression. This idea was further strengthened by the association of MHC class I loss with a poorer degree of differentiation as reported for breast (Wintzer et al., 1990) , colon (Momburg et al., 1986 ) and laryngeal (Lopez-Nevot et al., 1989) (Wintzer et al., 1990; Concha et al., 1991) .
This study shows that down-regulation of antigenpresenting and antigen-transporting molecules is a common phenomenon in NSCLC. Specific allelic loss (A2) was also frequently detected and it might be of interest to study the expression of the entire allelic repertoire present on tumour cells. Although no correlation was found with chnicopathological parameters, the understanding of the underlying mechanisms that are responsible for this defective expression, would be of paramount importance.
